A CR-UK Phase I Trial of LY3143921

Conditions:   a. Colorectal Cancer;   b. High Grade Serous Ovarian Cancer;   c. Non Small-cell Lung Cancer (Squamous Cell Variant);   d. Squamous Carcinoma of the Oesophagus;   e. Squamous Carcinoma of the Head and Neck (HPV Negative);   f. Urothelial Cancer;   g. Breast Cancer (Triple Negative Type);   h. Pancreatic Cancer
Intervention:   Drug: LY3143921 hydrate
Sponsor:   Cancer Research UK
Not yet recruiting - verified March 2017

http://ift.tt/2nDI15L